Sha Ha | VP, CMC
IGM Infectious Diseases, Inc.

Sha Ha, VP, CMC, IGM Infectious Diseases, Inc.

Sha Ha is the Vice President of CMC at IGM Biosciences. She oversees drug substance and drug product development as well as analytical development in the Doylestown PA site. Before joining IGM, Sha was the director of Vaccine Process Development and Commercialization at Merck.  She managed Phase 3 process characterization, tech transferring to CMOs, manufacturing facility design, and process validation for live virus vaccines. In her 15 years at Merck, Sha has worked on biologics and vaccines for Human Papillomavirus (HPV), Chikungunya, Dengue, Ebola, Cytomegalovirus (HCMV), and Streptococcus Pneumoniae. Her efforts in formulation, process and analytical have directly contributed to the filing, approval, and sustainable manufacturing of GARDASIL®9, VAXNEUVANCE®, and ERVEBO®. Prior to Merck, Sha was a research scientist in antibody discovery at Bayer HealthCare Pharmaceuticals for 6 years. Sha received her Ph.D. in Chemistry from Princeton University in 2001 and B.S. from Peking University in 1996. 


WVIC/WAC Pre-Congress Workshops - Nov 28 @ 14:00

Workshop B [Room: Constellation B]

Antibody Drug Discovery for Infectious Diseases

2pm – 5pm

2pm: Chair opening remarks: Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

Presentations 2.10pm – 4pm:

Shark-derived nanobodies for diagnostic and therapeutic use

Dr Helen Dooley, Assistant Professor, University of Maryland School of Medicine

Developing high affinity, high avidity, IgM antibodies for the prevention and treatment of infectious diseases

Dr Sha Ha, VP, CMC, IGM Biosciences

Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants 

Dr Shivshankar “Shankar” Sundaram, Director, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus

Dr Haoyang Li, Instructor, Center for Infectious Disease and Vaccine Research

La Jolla Institute for Immunology, LaJolla Institute

Tackling viral infections by human monoclonal antibodies

Dr Colin Havenar-Daughton, Director of Immunology, Vir Biotechnology

4.00-5:00pm Panel & Q&A with speakers: Overcoming hurdles in antibodies discovery and development against viral infection

  • How to develop antibodies that are resistant to viral mutations? 
  • How can the cost be justified if other therapeutics are available?
  • What effects has the pandemic had in increasing desire for therapeutic antibodies
  • The role of FC and FC modifications to enhance effector function
last published: 01/Dec/22 17:25 GMT

back to speakers

For conference programme and speaking opportunities:
Lauren Sheppard

For sponsorship and exhibition opportunities:
Thomas Hall